K67 Stock Overview
A contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Fortrea Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.10 |
| 52 Week High | US$36.60 |
| 52 Week Low | US$15.00 |
| Beta | 0 |
| 11 Month Change | -12.21% |
| 3 Month Change | -34.35% |
| 1 Year Change | -44.89% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -48.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| K67 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -5.6% | -1.1% | -2.2% |
| 1Y | -44.9% | 15.8% | 13.3% |
Return vs Industry: K67 underperformed the German Life Sciences industry which returned 15.9% over the past year.
Return vs Market: K67 underperformed the German Market which returned 13.6% over the past year.
Price Volatility
| K67 volatility | |
|---|---|
| K67 Average Weekly Movement | 6.9% |
| Life Sciences Industry Average Movement | 6.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: K67's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: K67's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2023 | 16,000 | Tom Pike | www.fortrea.com |
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum.
Fortrea Holdings Inc. Fundamentals Summary
| K67 fundamental statistics | |
|---|---|
| Market cap | €1.39b |
| Earnings (TTM) | -€198.13m |
| Revenue (TTM) | €2.77b |
0.5x
P/S Ratio-7.0x
P/E RatioIs K67 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| K67 income statement (TTM) | |
|---|---|
| Revenue | US$3.01b |
| Cost of Revenue | US$2.56b |
| Gross Profit | US$456.60m |
| Other Expenses | US$672.10m |
| Earnings | -US$215.50m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 08, 2024
| Earnings per share (EPS) | -2.41 |
| Gross Margin | 15.15% |
| Net Profit Margin | -7.15% |
| Debt/Equity Ratio | 76.9% |
How did K67 perform over the long term?
See historical performance and comparison